Τίτλος:
Lymphoprolipherative skin reactions induced by anti-TNFα: an open question
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Although anti-TNFα agents have revolutionized the treatment of many inflammatory diseases, various concerns have been reported regarding the risks of cancer development, as well as acceleration of the progression of subclinical, preexisting malignancies. In this case series, we investigated the provocative effect of anti-TNFα drugs in the development of cutaneous mycosis fungoides (MF)-like lymphoproliferative reactions. We describe five patients aged between 25–63 diagnosed with autoimmune disorders (psoriatic arthritis–one patient, Crohn’s disease–one patient and ankylosing spondylitis–three patients) who received anti-TNFα agents before the development of a cutaneous lymphoproliferative reaction. Histological and immunophenotypical analysis was typical for mycosis fungoides in all of them. Anti-TNFα agents were stopped with regression of the skin rash. A direct effect of anti-TNFα agents in the development of lymphoproliferative reactions (including MF) is suggested and further analyzed. Treatment cessation can be therapeutic. © 2019, © 2019 Taylor & Francis Group, LLC.
Συγγραφείς:
Nikolaou, V.
Gerochristou, M.
Marinos, L.
Economidi, A.
Voudouri, D.
Rigopoulos, D.
Stratigos, A.J.
Περιοδικό:
Journal of Dermatological Treatment
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
adalimumab; infliximab; monoclonal antibody, adult; ankylosing spondylitis; Article; case report; clinical article; Crohn disease; drug withdrawal; erythroderma; female; histopathology; human; immunophenotyping; lymphocyte structure; lymphoproliferative disease; male; middle aged; mycosis fungoides; phototherapy; priority journal; psoriatic arthritis; rash; skin defect; ulcerative colitis; lymphoproliferative disease; pathology; skin, Adalimumab; Adult; Antibodies, Monoclonal; Arthritis, Psoriatic; Crohn Disease; Humans; Infliximab; Lymphoproliferative Disorders; Male; Middle Aged; Skin; Spondylitis, Ankylosing
DOI:
10.1080/09546634.2019.1579889
